1. Home
  2. IMUX vs CUE Comparison

IMUX vs CUE Comparison

Compare IMUX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • CUE
  • Stock Information
  • Founded
  • IMUX 2016
  • CUE 2014
  • Country
  • IMUX United States
  • CUE United States
  • Employees
  • IMUX N/A
  • CUE N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • CUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMUX Health Care
  • CUE Health Care
  • Exchange
  • IMUX Nasdaq
  • CUE Nasdaq
  • Market Cap
  • IMUX 86.3M
  • CUE 91.9M
  • IPO Year
  • IMUX N/A
  • CUE 2018
  • Fundamental
  • Price
  • IMUX $0.98
  • CUE $1.26
  • Analyst Decision
  • IMUX Strong Buy
  • CUE Strong Buy
  • Analyst Count
  • IMUX 6
  • CUE 5
  • Target Price
  • IMUX $12.67
  • CUE $5.00
  • AVG Volume (30 Days)
  • IMUX 1.0M
  • CUE 285.1K
  • Earning Date
  • IMUX 02-20-2025
  • CUE 03-10-2025
  • Dividend Yield
  • IMUX N/A
  • CUE N/A
  • EPS Growth
  • IMUX N/A
  • CUE N/A
  • EPS
  • IMUX N/A
  • CUE N/A
  • Revenue
  • IMUX N/A
  • CUE $9,532,000.00
  • Revenue This Year
  • IMUX N/A
  • CUE $73.11
  • Revenue Next Year
  • IMUX N/A
  • CUE $11.02
  • P/E Ratio
  • IMUX N/A
  • CUE N/A
  • Revenue Growth
  • IMUX N/A
  • CUE 149.53
  • 52 Week Low
  • IMUX $0.92
  • CUE $0.45
  • 52 Week High
  • IMUX $2.11
  • CUE $2.58
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 44.34
  • CUE 49.50
  • Support Level
  • IMUX $0.94
  • CUE $1.27
  • Resistance Level
  • IMUX $1.02
  • CUE $1.50
  • Average True Range (ATR)
  • IMUX 0.06
  • CUE 0.12
  • MACD
  • IMUX 0.00
  • CUE -0.01
  • Stochastic Oscillator
  • IMUX 44.96
  • CUE 53.73

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Share on Social Networks: